Some of the most expensive drugs currently in use are gene therapies to treat specific diseases, and their high cost limits ...
The U.S. Food and Drug Administration has awarded the National Institute for Pharmaceutical Technology and Education a grant worth up to $35 million over the next five years to improve drug ...
The U.S. Food and Drug Administration announced it will relax certain rules for approving low-cost versions of some ...
From the moment we could look up to the skies, humanity has dreamt of what’s up there. And once we got there, how could we master it? And now that we’re there all the time, how can we use it? In 2025, ...
What is Pharma 4.0? The term Industry 4.0 refers to the fourth industrial revolution, associated with the application of advanced technologies that have dramatically changed the landscape of ...
2don MSN
FDA to streamline approvals for generic biological drugs in latest move targeting health costs
The US Food and Drug Administration will take steps to streamline the process to develop generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to ...
Hosted on MSN
A 19-year-old won $100,000 for inventing a cheaper, faster way to make antiviral drugs out of corn husks
When Adam Kovalčík flew to Ohio for an international science competition, he did not expect to come home with $100,000. The 19-year-old from Dulovce, Slovakia won that sum on Friday, though, because ...
Throughout 2025, drugmakers of all stripes have collectively poured billions of dollars into U.S. manufacturing investments.
This milestone marks the approval of the first product to get U.S. FDA clearance for commercial supply from Kemwell’s Bengaluru drug-product facility since the site became a dedicated biologics campus ...
Ajinomoto Bio-Pharma Services and Olon S.p.A. have entered into a strategic partnership to deliver drug substance manufacturing services.
The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may ...
Adam Kovalčík, age 19, innovated a cheaper, faster way to produce an antiviral drug. Galidesivir targets RNA viruses like COVID-19, Ebola, and Zika but hasn't completed clinical trials. Kovalčík won a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback